Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
[DOI] [PMC free article] [PubMed] [Google Scholar] 249.Yoder SM, Yang Q, Kindel TL, Tso P
BMJ Open 2013, 3(1)
Also published in the New England Journal of Medicine in 2022, the SURMOUNT-1 trial demonstrated that tirzepatide at the 15 mg dose produced an average weight loss of 22.5% of body weight over 72 weeks approaching results typically seen with bariatric surgery (Jastreboff et al., 2022, PMID: 35658024)
After 68 weeks of semaglutide 2.4 mg weekly, participants lost an average of 15% of body weight compared to 2.4% with placebo
The reduction of cardiovascular events is not only related to anti-diabetic properties, but also to pleotropic effects leading to the reduction of the residual cardiovascular risk, that has been defined as the risk of progression of CV events (MACE or HF) that remains after the optimal glycaemic control in T2DM patients, and it seems to be related to meta-inflammation, defined as a low-grade chronic and sterile inflammatory status
Efficacy of GLP-1 agonists in psychiatric illnesses
US$ 24.54
US$ 20.88
US$ 23.94
US$ 23.01
US$ 29.69
US$ 21.10
US$ 25.71
US$ 25.58
